company background image
MVP

Medical Developments International ASX:MVP Stock Report

Last Price

AU$2.66

Market Cap

AU$199.7m

7D

-6.7%

1Y

-46.7%

Updated

25 May, 2022

Data

Company Financials +
MVP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MVP Stock Overview

Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices.

Medical Developments International Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medical Developments International
Historical stock prices
Current Share PriceAU$2.66
52 Week HighAU$5.45
52 Week LowAU$2.80
Beta1.21
1 Month Change-25.49%
3 Month Change-26.32%
1 Year Change-46.69%
3 Year Change-49.81%
5 Year Change-43.52%
Change since IPO454.17%

Recent News & Updates

Mar 04
Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

The latest analyst coverage could presage a bad day for Medical Developments International Limited ( ASX:MVP ), with...

Shareholder Returns

MVPAU PharmaceuticalsAU Market
7D-6.7%-3.7%-1.2%
1Y-46.7%-17.9%-0.009%

Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned -17.9% over the past year.

Return vs Market: MVP underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is MVP's price volatile compared to industry and market?
MVP volatility
MVP Average Weekly Movement11.5%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement9.3%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: MVP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MVP's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200368Brent MacGregorhttps://medicaldev.com

Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain in trauma; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, resuscitation kits, oxygen therapy masks, and resuscitators.

Medical Developments International Fundamentals Summary

How do Medical Developments International's earnings and revenue compare to its market cap?
MVP fundamental statistics
Market CapAU$199.65m
Earnings (TTM)-AU$18.81m
Revenue (TTM)AU$22.30m

8.5x

P/S Ratio

-10.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MVP income statement (TTM)
RevenueAU$22.30m
Cost of RevenueAU$7.37m
Gross ProfitAU$14.93m
Other ExpensesAU$33.73m
Earnings-AU$18.81m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin66.95%
Net Profit Margin-84.35%
Debt/Equity Ratio0%

How did MVP perform over the long term?

See historical performance and comparison
New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


53.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MVP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MVP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MVP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MVP's revenue (43.1% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: MVP's revenue (43.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MVP is forecast to be unprofitable in 3 years.


Past Performance

How has Medical Developments International performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-85.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MVP is currently unprofitable.

Growing Profit Margin: MVP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MVP is unprofitable, and losses have increased over the past 5 years at a rate of 85.8% per year.

Accelerating Growth: Unable to compare MVP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MVP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).


Return on Equity

High ROE: MVP has a negative Return on Equity (-30.33%), as it is currently unprofitable.


Financial Health

How is Medical Developments International's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MVP's short term assets (A$40.5M) exceed its short term liabilities (A$9.1M).

Long Term Liabilities: MVP's short term assets (A$40.5M) exceed its long term liabilities (A$24.9M).


Debt to Equity History and Analysis

Debt Level: MVP is debt free.

Reducing Debt: MVP has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MVP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MVP has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 37.7% each year.


Dividend

What is Medical Developments International current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: MVP is not paying a notable dividend for the Australian market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MVP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Brent MacGregor (57 yo)

1.5yrs

Tenure

AU$1,325,143

Compensation

Mr. Brent MacGregor serves as Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since November 01, 2020. Mr...


CEO Compensation Analysis

Compensation vs Market: Brent's total compensation ($USD936.76K) is above average for companies of similar size in the Australian market ($USD291.26K).

Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.


Leadership Team

Experienced Management: MVP's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: MVP's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medical Developments International Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Medical Developments International Limited
  • Ticker: MVP
  • Exchange: ASX
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$199.654m
  • Shares outstanding: 71.31m
  • Website: https://medicaldev.com

Number of Employees


Location

  • Medical Developments International Limited
  • 4 Caribbean Drive
  • Scoresby
  • Victoria
  • 3179
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.